News
Sobi & Apellis’ Aspaveli/Empaveli demonstrates sustained one-year efficacy in phase 3 study for rare kidney diseases: Stockholm Monday, June 9, 2025, 10:00 Hrs [IST] Sobi, a glo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback